Homepage>Company>Media>Pharma News>2016>Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer's disease
Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer's disease